腹腔STN刺激与帕金森病的轴向运动结果的改善有关
Madison Butler1, Asra Askari2, Brandon Zhu3
1University of Michigan, Neurology, Ann Arbor, MI, 48105, USA. madisobu@med.umich.edu.
Journal of neural transmission (Vienna, Austria : 1996)
|April 24, 2025
概括
脑下核深度大脑刺激 (DBS) 改善了帕金森病的轴向运动症状. 最佳的结果与右侧更多的腹部电极接触位置有关.
科学领域:
- 神经外科 神经外科
- 神经学 神经学
- 运动障碍 运动障碍
背景情况:
- 脑下核 (STN) 深度大脑刺激 (DBS) 对帕金森病 (PD) 中的尾运动症状有效.
- 在PD中,STN DBS对轴运动标志的影响仍然不太清楚.
- 在STN中的电极接触位置可能会影响电机结果的变化.
研究的目的:
- 调查STN DBS在晚期PD中对轴运动症状的疗效.
- 为了确定活性电极接触位置对轴向电机结果的影响.
主要方法:
- 在70名晚期PD患者中评估了轴运动得分,在双边STN DBS后6-12个月.
- 使用重复测量ANOVA来比较跨治疗条件 (药物/刺激) 的轴向得分.
- 采用多重线性回归来将电极接触位置与轴电机得分相关联.
主要成果:
- 与OFF MED-OFF STIM条件相比,STN DBS的总轴分数显著改善 (p < 0.0001).与OFF MED-OFF STIM条件相比,STN DBS的总轴分数显著改善 (p < 0.0001).与OFF MED-OFF STIM条件相比,STN DBS的总轴分数显著改善 (p < 0.0001).
- 右侧的更多的背部电极接触与轴向得分的恶化相关 (斜率 = 0.407,p = 0.0047).
- 在右侧的前腹STN区域进行刺激时,观察到轴向得分的改善.
结论:
- 在手术后6-12个月的PD患者中,STN DBS在改善总轴分数和子分数方面表现出有效性.
- 右侧的更多腹部电极接触位置与更好的轴向症状改善有关.
- 需要进一步的研究来确认在DBS队列中对轴性症状管理的最佳STN刺激目标.
相关概念视频
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499


